Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company's total debt is โน565.68 Billion. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2024-12-31 | โน568.79 B | -6.89% |
2023-12-31 | โน610.89 B | 11.62% |
2022-12-31 | โน547.30 B | -3.29% |
2021-12-31 | โน565.93 B | -1.15% |
2020-12-31 | โน572.50 B | 26.08% |
2019-12-31 | โน454.07 B | 9.39% |
2018-12-31 | โน415.09 B | 9.48% |
2017-12-31 | โน379.15 B | -14.39% |
2016-12-31 | โน442.88 B | 2.12% |
2015-12-31 | โน433.70 B | 1072.98% |
2014-12-31 | โน36.97 B | 0.44% |
2013-12-31 | โน36.81 B | -41.06% |
2012-12-31 | โน62.46 B | 10.96% |
2011-12-31 | โน56.29 B | 4.38% |
2010-12-31 | โน53.93 B | 5.67% |
2009-12-31 | โน51.03 B | -4.6% |
2008-12-31 | โน53.50 B | -12.78% |
2007-12-31 | โน61.33 B | 1332.29% |
2006-12-31 | โน4.28 B | 119.06% |
2005-12-31 | โน1.95 B | -94.69% |
2004-12-31 | โน36.82 B | -8.84% |
2003-12-31 | โน40.39 B | -2.75% |
2002-12-31 | โน41.53 B | 1724.46% |
2001-12-31 | โน2.27 B | -55.38% |
2000-12-31 | โน5.10 B | 3.81% |
1999-12-31 | โน4.91 B | 43.91% |
1998-12-31 | โน3.41 B | -5.07% |
1997-12-31 | โน3.59 B | 51.02% |
1996-12-31 | โน2.38 B |